Quantitative metabolic volumetric product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in assessing treatment response to disease-modifying antirheumatic drugs in rheumatoid arthritis: Multiparametric analysis integrating American college of Rheumatology/European League against Rheumatism criteria

Quantitative metabolic volumetric product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in assessing treatment response to disease-modifying antirheumatic drugs in rheumatoid arthritis: Multiparametric analysis integrating American college of Rheumatology/European League against Rheumatism criteria

The purpose of this study was to assess the role of fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the evaluation of treatment response evaluation to disease-modifying antirheumatic drug (DMARD) therapy in patients of rheumatoid arthritis (RA). A total of t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nandigam Kumar, Yogesh Shejul, Ramesh Asopa, Sandip Basu
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2017-10-01
Series:	World Journal of Nuclear Medicine
Subjects:	18fluorine-2fluoro-2-deoxy-d-glucose-positron emission tomography/ computed tomography 2010 american college of rheumatology/ european league against rheumatism rheumatoid classification criteria disease-modifying antirheumatic drugs metabolic volumetric product rheumatoid arthritis
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.215492
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Role of [18F] Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Tonsillar Carcinoma in a Patient with Multiple Primary Carcinomas
by: Patrick Earl Amparado Fernando, et al.
Published: (2019-01-01)

18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for preoperative planning in a rare case of hyperfunctional bilateral adrenocortical carcinoma and review of literatures
by: Apichaya Claimon, et al.
Published: (2020-07-01)

Diagnostic value of sentinel lymph node scintigraphy and 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the detection of metastatic lymph nodes in patients with early-stage cervical cancer
by: Florette Reyneke, et al.
Published: (2020-07-01)

Appearance of adrenal myelolipomas on 2-deoxy-2-(18F) fluoro-D-glucose positron emission tomography-computed tomography
by: Steven Rowe, et al.
Published: (2017-10-01)

Corrigendum: Case report: 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography image findings of a dog with gossypiboma
by: Su-Hyeon Kim, et al.
Published: (2024-10-01)

Characterization of Pulmonary Sclerosing Pneumocytoma Assessed by 18F‐FDG PET/CT
by: Jie Xu, et al.
Published: (2025-07-01)

Lynch Syndrome Associated Colon Adenocarcinoma Resembling Lymphoma on Fluoro-Deoxyglucose-Positron Emission Tomography/Computed Tomography
by: Carina Aparici, et al.
Published: (2015-07-01)

Head-to-head comparison of [18F]-fluorodeoxyglucose and [18F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series
by: Tanyaluck Thientunyakit, et al.
Published: (2020-01-01)

Discordant findings of different positron emission tomography/CT tracers in a case of glioblastoma
by: Ram Kumar, et al.
Published: (2021-10-01)

Primary Retroperitoneal Seminoma Staging and Surveillance by Means of Fluoro-2-Deoxyglucose-Positron Emission Tomography/Computed Tomography
by: Tianye Liu, et al.
Published: (2015-04-01)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01)

Presentation of unusual tracheal metastasis on Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography after 9 years in postnephrectomy patient of renal cell carcinoma: A case report and review of literature
by: Rahul Parghane, et al.
Published: (2017-07-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Detection of primary malignancy and metastases with FDG PET/CT in patients with cholangiocarcinomas: Lesion-based comparison with contrast enhanced CT
by: Youssef Elias, et al.
Published: (2016-07-01)

Comparison of the Efficacy and Safety of Disease‐Modifying Antirheumatic Drugs Combination Therapies: A Systematic Review and Network Meta‐Analysis
by: Linfeng Liu, et al.
Published: (2025-03-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Antirheumatic Medication Calendar Significantly Improves Adherence in First-Time Methotrexate Users: A Prospective, Single-Blind, Randomized Controlled Trial
by: Yuan F, et al.
Published: (2025-07-01)

Gemcitabine-Loaded Microbeads for Transarterial Chemoembolization of Rabbit Renal Tumor Monitored by <sup>18</sup>F-FDG Positron Emission Tomography/X-Ray Computed Tomography Imaging
by: Xiaoli Zhang, et al.
Published: (2024-12-01)

Prognostic Value of Fluoro-D-glucose Uptake of Primary Tumor and Metastatic Lesions in Advanced Nonsmall Cell Lung Cancer
by: Xuan Nguyen, et al.
Published: (2014-04-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Body composition and skeletal muscles status in patients with rheumatoid arthritis during treatment with biologic disease-modifying antirheumatic drugs
by: O. V. Dobrovolskaya, et al.
Published: (2025-02-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2023-07-01)

EUROPEAN CONGRESS OF RHEUMATOLOGY (MADRID, 12–15 JUNE 2013): PROBLEMS ON RHEUMATOID ARTHRITIS
by: Anastasia Sergeevna Avdeeva, et al.
Published: (2013-12-01)

A Case of Severe Methotrexate Toxicity: Clinical Insights and Management
by: Pradnya Diggikar, et al.
Published: (2025-03-01)

Active herpes zoster infection involving lumbosacral dermatome, an unusual site of manifestation and incidental finding in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography scan
by: Deepa Singh, et al.
Published: (2018-01-01)

Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

Improving 18F-Fluoro-D-Glucose-Positron Emission Tomography/Computed Tomography Imaging in Alzheimer′s Disease Studies
by: Karin Knešaurek
Published: (2015-07-01)

The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties
by: Garmish O, et al.
Published: (2025-08-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

THE EUROPEAN CONGRESS OF RHEUMATOLOGY, ROME (10–13 JUNE 2015): PROBLEMS OF RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2016-02-01)

Cone-Beam Computed Tomography: Fractal Analysis of Osseous Changes in Temporomandibular Joint for Rheumatoid Arthritis Patients: A Retrospective Study
by: S Jayachandran, et al.
Published: (2022-01-01)

Teleteaching in paediatric rheumatology: an Asia Pacific League of Associations for Rheumatology experience
by: Sumaira Farman, et al.
Published: (2024-04-01)

Extraskeletal osteosarcoma: An uncommon variant with rare metastatic sites detected with FDG PET/CT
by: Ameya D. Puranik, et al.
Published: (2014-01-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Two decades of fluorine chemistry in Cergy
by: Pytkowicz, Julien, et al.
Published: (2024-12-01)

Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis
by: Tobias Schwarz, et al.
Published: (2025-05-01)

Fluorine-18-Labeled Positron Emission Tomography Probe Targeting Activated p38α: Design, Synthesis, and In Vivo Evaluation in Rodents
by: Mikiya Futatsugi, et al.
Published: (2025-04-01)